Clinical Trials Logo

Neoplasm Metastasis clinical trials

View clinical trials related to Neoplasm Metastasis.

Filter by:

NCT ID: NCT03585673 Recruiting - Metastatic Cancer Clinical Trials

Docetxel-PM and Oxaliplatin for Esophageal Carcinoma

DOSE
Start date: June 1, 2018
Phase: Phase 2
Study type: Interventional

Esophageal or esophageal-gastric junction squamous cell cancer has dismal prognosis. And still no promissing chemotherapeutic drugs is excisted. In this study, we wanted to look at the effects and safety of first line docetaxel-PM and oxaliplatin weekly administration chemotherapy for the patients with inoperable or metastatic esophageal squamous cell carcinoma.

NCT ID: NCT03577665 Recruiting - Colorectal Cancer Clinical Trials

Curative Proton Beam Therapy for Patients With Liver Metastasis of Colorectal Cancer

Start date: May 21, 2018
Phase: N/A
Study type: Interventional

Proton alone therapy is performed -> 5 times a week, 7200 cGy / 15 fractions for 3 weeks total

NCT ID: NCT03570619 Not yet recruiting - Metastatic Cancer Clinical Trials

Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

IMPACT
Start date: August 2018
Phase: Phase 2
Study type: Interventional

This study will attempt to determine the efficacy of checkpoint inhibitor immunotherapy with nivolumab and ipilimumab combination therapy followed by nivolumab monotherapy in patients with metastatic prostate cancer harboring loss of CDK12 function.

NCT ID: NCT03569241 Recruiting - Prostate Cancer Clinical Trials

PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases

STORM
Start date: April 27, 2018
Phase: Phase 2
Study type: Interventional

A proportion of prostate cancer (PCa) patients develop relapse following curative local treatment. Regional nodal recurrence is an emerging clinical situation since the introduction of new molecular imaging methods in the restaging of recurrent prostate cancer. More specifically, a subgroup of these patients is being diagnosed with a recurrence confined to the regional lymph nodes and limited in number (oligorecurrence) using choline or PSMA PET-CT. As there are no specific treatment recommendations for these type of patients, different treatment approaches are currently used, mostly focusing on local ablative treatments using radiotherapy or surgery. These treatments are coined metastasisdirected therapy (MDT). MDT in combination with or without temporary ADT could delay the subsequent risk of progression, and even cure limited regional nodal recurrences. Consequently, lifelong palliative ADT, with its toxicity and excess in non-cancer mortality might be postponed. The proposed trial randomizes patients with oligorecurrent nodal prostate cancer following primary PCa treatment to either metastasis-directed therapy (MDT) (salvage lymph node dissection, sLND or stereotactic body radiotherapy, SBRT) or MDT plus whole pelvis radiotherapy (WPRT: 45 Gy in 25 fractions).

NCT ID: NCT03566797 Not yet recruiting - Clinical trials for Secondary Sclerosis Cholangitis in Critically Ill Patients

Secondary Sclerosis Cholangitis Prospective

SSCpro
Start date: July 1, 2018
Phase:
Study type: Observational

SC-CIP is increasing in patients after critical illness. Pathogenesis is still largely unclear. Gut microbiome composition, gut permeability, bacterial translocation, inflammation and/or genetic variants contribute to the pathogenesis The aim of this project is to study gut microbiome composition, gut permeability, bacterial translocation, inflammation, bile acid composition and genetic polymorphisms by conducting a prospective cohort study in patients with a high risk to develop SC-CIP.

NCT ID: NCT03566355 Recruiting - Colorectal Cancer Clinical Trials

Curative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer

Start date: May 23, 2018
Phase: N/A
Study type: Interventional

Proton alone therapy is performed -> 5 times a week, 7200 cGy / 15 fractions for 3 weeks total

NCT ID: NCT03563326 Active, not recruiting - Clinical trials for Metastases, Neoplasm

Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)

Start date: April 1, 2018
Phase: Phase 1
Study type: Interventional

To investigate the safety and efficacy of intraperitoneal infusion of EpCAM CAR-T cell in advanced gastric cancer with peritoneal metastasis by a prospective nonrandomized controlled trial.

NCT ID: NCT03562234 Not yet recruiting - Colorectal Cancer Clinical Trials

The CLiFF Study: Change in Liver Function and Fat in Pre-operative Chemotherapy for Colorectal Liver Metastases

CLiFF
Start date: August 2018
Phase:
Study type: Observational

The CLiFF Study will assess changes in liver function and liver fat in patients with colorectal liver metastases (CLM) undergoing pre-operative chemotherapy before liver resection. There will be no change to the standard treatment for CLM. The change in liver fat will be assessed using novel magnetic resonance techniques and the change in liver function will be measured using a newly-developed fully-licensed breath test to give the most accurate measure of liver function possible. Understanding if these changes are related or reversible will help to understand the relationship between obesity and cancer. This is an important issue, as obesity is now the second most common cause of cancer worldwide.

NCT ID: NCT03561896 Recruiting - Clinical trials for Brain Metastases, Adult

Hypofractionated Brain Radiationcavity

Start date: January 2015
Phase: N/A
Study type: Interventional

Stereotactic radiosurgery or hypofractionated radiotherapy of the resection cavity after metastasectomy in cancer patients with brain metastases

NCT ID: NCT03558607 Recruiting - Clinical trials for Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder

The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm

Start date: July 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This trial aimed to investigate the therapeutic efficacy of ruxolitinib in combination with cytotoxic chemotherapy for post-myeloproliferative neoplasm secondary acute myeloid leukemia.